2,3-dichloro-5-ethoxy-6-hydroxybenzaldehyde | 364595-45-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,3-dichloro-5-ethoxy-6-hydroxybenzaldehyde
• CAS: 364595-45-9
• 化学式: C₉H₈Cl₂O₃
• mdl: MFCD04084099
• 分子量: 235.067
• InChiKey: JSGAXHIVNSHPRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,3-dichloro-5-ethoxy-6-hydroxybenzaldehyde 、 2-溴苯甲酰肼 在 magnesium sulfate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 (E)-2-bromo-N-(‘2,3-dichloro-5-ethoxy-6-hydroxybenzylidene)benzohydrazide
  参考文献：
  名称：

  WO2018/107853

  摘要：

  公开号：
• 作为产物：
  描述：

  3-乙氧基水杨醛 在 N-氯代丁二酰亚胺 、 溶剂黄146 作用下， 以89%的产率得到2,3-dichloro-5-ethoxy-6-hydroxybenzaldehyde
  参考文献：
  名称：

  WO2018/107853

  摘要：

  公开号：

文献信息

• 단백질 티로신 키나아제를 저해하는 화합물 및 이것을 포함하는 암의 치료용 또는 예방용 약학 조성물
  申请人：UIF (University Industry Foundation), Yonsei University 연세대학교 산학협력단(220050095099) BRN ▼110-82-10500

  公开号：KR101639289B1

  公开（公告）日：2016-07-13

  본 발명은 신규 화합물 및 이것의 제조방법에 관한 것으로서, 특히 단백질 티로신 키나아제의 비정상적 활성과 관련된 질환을 치료 또는 예방할 수 있는 약학 조성물에 관한 것이다.

  本发明涉及一种新化合物及其制备方法，特别是涉及一种药学组合物，可以治疗或预防与蛋白酪氨酸激酶异常活性相关的疾病。
• TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：EVEN Luc

  公开号：US20100041651A1

  公开（公告）日：2010-02-18

  The invention relates to the triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives of general formula (I): Wherein X, A, R 1 and R 2 are as defined herein. The invention further relates to preparation methods and therapeutic use thereof.

  本发明涉及一般式(I)的三唑并吡啶羧酰胺衍生物和三唑并嘧啶羧酰胺衍生物，其中X、A、R1和R2如本文所定义。本发明还涉及其制备方法和治疗用途。
• PDZ DOMAIN MODULATORS
  申请人：Gether Ulrik

  公开号：US20100249165A1

  公开（公告）日：2010-09-30

  This invention relates to compounds useful as PDZ domain modulators, in particular the PDZ domain of PICK1. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions.

  本发明涉及用作PDZ结构域调节剂的化合物，特别是用于PICK1的PDZ结构域。在其他方面，本发明涉及这些化合物在治疗方法中的应用以及药物组成物。
• N-methyl-d-aspartate receptor allosteric modulators and methods for their use
  申请人：Qingdao Primedicine Pharmaceutical Company, Ltd.

  公开号：US11166924B2

  公开（公告）日：2021-11-09

  This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.

  本发明涉及治疗化合物和组合物，以及将其用于预防或治疗神经系统疾病的方法。特别是，本发明涉及N-甲基-D-天冬氨酸受体（NMDAR）异位调节剂及其用于预防或治疗由NMDAR功能障碍引起或与之相关的紊乱或病症的方法。本发明还涉及一种鉴定NMDAR别构调节剂的方法。
• Discovery of ( E )-5-(benzylideneamino)-1 H -benzo[ d ]imidazol-2(3 H )-one derivatives as inhibitors for PTK6
  作者：Hyun Jae Shim、Hye Ran Yang、Han Ie Kim、Shin-Ae Kang、Kyoung Tai No、Young Hoon Jung、Seung-Taek Lee

  DOI：10.1016/j.bmcl.2014.08.036

  日期：2014.10

  A lead compound 1, which inhibits the catalytic activity of PTK6, was selected from a chemical library. Derivatives of compound 1 were synthesized and analyzed for inhibitory activity against PTK6 in vitro and at the cellular level. Selected compounds were analyzed for cytotoxicity in human foreskin fibroblasts using MTT assays and for selectivity towards PTK members in HEK 293 cells. Compounds 20 (in vitro IC50=0.12μM) and 21 (in vitro IC50=0.52μM) showed little cytotoxicity, excellent inhibition of PTK6 in vitro and at the cellular level, and selectivity for PTK6. Compounds 20 and 21 inhibited phosphorylation of specific PTK6 substrates in HEK293 cells. Thus, we have identified novel PTK6 inhibitors that may be used as treatments for PTK6-positive carcinomas, including breast cancer.